Lv1
50 积分 2020-12-09 加入
Applied Biopharmaceutics and Pharmacokinetics, Leon Shargel and Andrew B. C. Yu
3小时前
求助中
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
1个月前
已完结
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
2个月前
已完结
Traditional Chinese medicine syndrome differentiation and treatment by stages of Parkinson’s disease: study protocol for a multicentre, randomized, double-blind, placebo-controlled clinical trial
9个月前
已完结
Elranatamab: First Approval
10个月前
已完结
Antibody-based Phenotypic Screening – the Discovery of Oleclumab (MEDI9447)
2年前
已关闭
Pharmacology, pharmacokinetics, and toxicity characterization of a novel anti-CD73 therapeutic antibody IBI325 for cancer immunotherapy
2年前
已完结
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial
2年前
已完结
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial
2年前
已完结
皖公网安备34019202002308
